Ribavirina

Ribavirina

Bibliografia - Quali fonti bibliografiche per Ribavirina?

1. Agenzia Italiana del Farmaco - AIFA, Copegus - Riassunto delle caratteristiche del Prodotto, 2012, disponibile online https://farmaci.agenziafarmaco.gov.it/aifa/servlet/HomeDispatcher

2. American Academy of Pediatrics. Red Book: 2009 Report of the Committee on Infectious Desease. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009.

3. Amorosa V.K. et al., Antivir. Ther., 2010, 15 (1), 91.

4. Ando K. et al., Case Report Gastroenterol., 2009, 3 (3), 372.

5. Barnes D.J., Doursew M., Reference dose: Description and use in health risk assessments. Regul Tox. and Pharm., 1988, Vol. 8, 471.

6. Benarroch D. et al., J. Biol. Chem., 2004, 279 (34), 35638.

7. Bougie I., Bisaillon M., J. Biol. Chem., 2004, 279 (21), 22124.

8. Carrat F. et al., JAMA, 2004, 292 (23), 2839.

9. Cassidy, L. F., Patterson J. L., Antimicrob. Agents Chemother., 1989, 33, 2009.

10. CDC - Centers for Disease Control and Prevention, Travelers’ Health. Chapter 3 Infectious Disease Related to Travel, 2013, disponibile on line http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/viral-hemorrhagic-fevers

11. Centers for Disease Control (CDC), MMWR Morb. Mortal Wkly. Rep., 1988, 37 (36), 560.

12. Chaudhari S. et al., Dig. Dis. Sci., 2004, 49 (6), 1000.

13. Conrad DA, et al. Pediatr. Infect Dis. J., 1987, 6 (2), 152.

14. De Francesci L. et al., Hepatology, 2000, 31(4), 997.

15. Decker J., Shults R.A., Health Hazard Evaluation Report No. HETA 91-104-229, 1992, June Florida Hospital, Orlando, Florida disponibile on line www.cdc.gov/niosh/hhe/reports/pdfs/1991-0104-2229.pdf

16. Eriksson, B. et al., Antimicrob. Agents Chemother., 1977, 11 (6), 946.

17. European Medicines Agency - EMA, Pegasys Product information, 2013a disponibile on line http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000395/human_med_000974.jsp&mid=WC0b01ac058001d124

18. European Medicines Agency - EMA, Rebetol® Product information, 2013, disponibile on line http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000246/human_med_001017.jsp&mid=WC0b01ac058001d124

19. Ferenci P., J. Antimicrob. Chemother., 2004, 53 (1), 15.

20. Fernandez-Larsson R. et al., Antimicrob. Agents Chemother., 7989, 33 (10), 1668.

21. Food and Drug Administration - FDA, Copegus Prescribing Information, 2013 disponibile on line http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo

22. Food and Drug Administration - FDA, Rebetol Prescribing Information, 2013a disponibile on line http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory

23. Food and Drug Administration - FDA, Ribasphere Prescribing Information, 2004 disponibile on line http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo

24. Food and Drug Administration. FDA drug safety communication: Serious skin reactions after combination treatment with the hepatitis C drugs Incivek (telaprevir), peginterferon alfa, and ribavirin, 2012 Dec 19.

25. Gane E.J. et al., NEJM, 2013, 368 (1), 34.

26. Gavin P.J., Katz B.Z., Pediatrics, 2002, 110 (1 Pt 1), e9.

27. Genentech. Copegus (ribavirin) tablets prescribing information. South San Francisco, CA, 2013.

28. Ghany M.G. et al. Hepatology, 2011, 54 (4), 1433.

29. Ghany M.G. et al., Hepatology 2009, 49, 1335.

30. Gordon K.B. et al. JAMA, 2003; 290 (23), 3073.

31. Jain K et al., Br. J. Ophthalmol., 2001, 85 (10), 1171.

32. Jonas M.M. et al., Hepatology, 2012, 56 (2), 523.

33. Kadmon Pharmaceuticals. Ribasphere (ribavirin) capsules prescribing information. Warrendale, PA, 2011 Jan.

34. Kamar N. et al., NEJM, 2014, 370 (12), 1111.

35. Kaplan J.E. et al. , MMWR Recomm. Rep., 2009, 58 (RR-4), 1.

36. Kelly D.A. et al., J. Viral Hepat., 2012, 19 (4), 263.

37. Kirk M. Chan Tack, Kirk M. Chan Tack, Jeffrey S. Murray, Debra B. Bimkrant. Food and Drug Administration, M.D. The New England Journal of Medicine. 2009, 361, 17.

38. Laguno M. et al., AIDS, 2004, 18 (13), F27.

39. Lhomme S. et al., Antimicrob. Agents Chemother., 2015, 60 (3), 1608.

40. Mardani M. et al., Clin. Infect. Dis., 2003, 36, 1613.

41. Merck & Co. Rebetol (ribavirin) capsules, oral solution prescribing information. Whitehouse Station, NJ; 2013 May.

42. Merck Sharp & Dohme Corporation. Victrelis (boceprevir) capsules prescribing information. Whitehouse Station, NJ; 2013 feb. 28, 14.

43. Mira J.A. et al., J. Antimicrob. Chemother., 2008, 62 (6), 1365.

44. Miyamura K. et al., Bone Marrow Transplant., 2000, 25 (5), 545.

45. MMWR, 1998, 37 (36), 560, disponibile on line http://www.cdc.gov/mmwr/preview/mmwrhtml/00001276.htm

46. Moreno A. et al., Antivir. Ther., 2004, 9 (1), 133.

47. Morfin F. et al., Antivir. Ther., 2005, 10 (2), 225.

48. Peyrin-Biroulet L. et al., Aliment. Pharmacol. Ther., 2008, 28 (8), 984.

49. Reichard O. et al., Lancet, 1998, 351 (9096), 83.

50. American association for Respiratory care, Respiratory Care, 1991, 36 (9), 916.

51. Riner A. et al., Postgrad. Med., 2009 121 (3), 139.

52. Rodriguez-Torres M. et al., Antimicrob. Agents Chemother., 2005, 49 (10), 3997.

53. Rusnak J.M., Applied Biosafety, 2011, 16 (2), 67.

54. Schleuning M. et al., Hematol. J., 2004, 5 (2), 135.

55. Shrestha N.K., Hamrock D.J., Clin. Infec. Dis., 2010, 51(1), e4–e6.

56. Smith R.A., Knight V., Smith J.A.D., Clinical applications of Ribavirin, Academica Press, Inc., NY. 1984, 65-77.

57. Smith R.A., Knight V., Smith J.A.D., Clinical applications of Ribavirin, Academica Press, Inc., NY. 1984, 79-92.

58. Solas C. et al., AIDS, 2012, 26 (17), 2193.

59. Stein D.S. et al., Antimicrob. Agents Chemother., 1987, 31 (8), 1285.

60. Streeter D.G. et al., Proc. Natl. Acad. Sci. USA, 1973, 70 (4), 1174.

61. Toltzis, P. et al., Antimicrob. Agents Chemother., 1988, 32 (4), 492.

62. US Army Medical Research Institute of Infectious Disease. USAMRIID’s medical management of biologic casualties handbook. 5th ed. USAMRIID: Fort Detrick, MD; 2004 Aug.

63. Valeant Pharmaceuticals International. Using the SPAG-2. Aliso Viejo, CA: 2005.

64. Valeant Pharmaceuticals, Inc. Virazole (ribavirin for inhalation solution) prescribing information. Aliso Viejo, CA: 2008 Nov.

65. Ventre K, Randolph AG. Cochrane Database Syst. Rev., 2007, 24 (1): CD000181.

66. Vertex Pharmaceuticals Incorporated. Incivek (telaprevir) film-coated tablets prescribing information. Cambridge, MA; 2013 Apr.

67. Vispo E. et al., Antivir. Ther., 2008, 13 (3), 429.

68. Wirth S. et al., J. Hepatol., 2010, 52 (4), 501.

69. Wray S.K. et al., Antiviral Res., 1985, 5 (1), 39.

70. Yang Z.Q. et al., Chin. Med. J. (Engl.), 1991, 104 (2), 149.

71. Yee H.S. et al., Am. J. Gastroenterol., 2012, 107 (5), 669.